Summary
Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on April 30, 2026, to report its financial results for the first quarter of 2026. The filing includes a press release detailing these results and a presentation on financial and operating initiatives, both of which are available on the company's website. Investors should note that the company is referencing non-GAAP financial information and provides reconciliations to GAAP measures within the furnished materials. This report serves as an announcement of the company's quarterly performance and strategic outlook. While specific financial figures are not detailed within the 8-K text itself, the furnished exhibits (Exhibit 99.1 and 99.2) are the primary sources for understanding BMY's performance and forward-looking statements for the first quarter of 2026. Investors are encouraged to review these exhibits for comprehensive details on revenue, profitability, and any strategic updates shared during the associated conference call.
Key Highlights
- 1BMY filed an 8-K on April 30, 2026, to announce Q1 2026 financial results.
- 2The filing includes a press release (Exhibit 99.1) and a presentation (Exhibit 99.2).
- 3These documents are available on the company's website (www.bms.com).
- 4The company is using non-GAAP financial measures and has provided reconciliations to GAAP.
- 5The furnished information should be reviewed in conjunction with the Q1 2026 earnings release and presentation.
- 6The information furnished under Item 7.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act, but is important for understanding current company performance.